Protalix BioTherapeutics (PLX) Tops Q3 EPS by 8c
Tweet
Share
E-mailGet Alerts PLX Hot Sheet
Price: $2.16 -2.7%
Revenue Growth %: -49.8%
Financial Fact:
COST OF REVENUES: -4.25M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Revenue Growth %: -49.8%
Financial Fact:
COST OF REVENUES: -4.25M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Protalix BioTherapeutics (NYSE: PLX) reported Q3 EPS of ($0.07), $0.08 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $5.4 million versus the consensus estimate of $5.7 million.
For earnings history and earnings-related data on Protalix BioTherapeutics (PLX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- C.H. Robinson acquires DeSpir Logistics for $75 million
- Credo Technology pops 3.5% as Evercore initiates with monster $325 price target
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
